IL17A and asthma: Experimental studies have found that XBCQD can alleviate the symptoms of obese asthma and lung inflammation, reduce serum IgE, reduce the expression of IL-6, IL-17, and IL-23 in serum, to reduce lung inflammation induced by obese asthma in mice; flow cytometry of spleen tissue showed that XBCQD reduced the proportion of Th17 cells and restored the proportion of Treg cells.